Correction: Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
February 09, 2024 08:32 ET
|
Nuvectis Pharma, Inc.
Fort Lee, NJ, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of...
Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
February 09, 2024 08:00 ET
|
Nuvectis Pharma, Inc.
Fort Lee, NJ, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of...
Nuvectis Pharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024 08:00 ET
|
Nuvectis Pharma, Inc.
Fort Lee, NJ, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of...
Nuvectis Pharma, Inc. Announces a Collaboration with Mayo Clinic to Evaluate NXP800 in an Investigator-Sponsored Clinical Trial in Cholangiocarcinoma
December 18, 2023 08:00 ET
|
Nuvectis Pharma, Inc.
Mitesh Borad, M.D., will serve as the Principal Investigator for the clinical trialThe Investigator-sponsored clinical trial follows the robust preclinical proof of concept data generated by...
Nuvectis Pharma, Inc. Reports Third Quarter 2023 Financial Results and Business Highlights
November 08, 2023 08:00 ET
|
Nuvectis Pharma, Inc.
Phase 1b Study of NXP800 in Patients with Platinum Resistant, ARID1a-Mutated Ovarian Carcinoma is Ongoing Initiated the Phase 1a Dose Escalation Study of NXP900 in Patients with Advanced Solid...
Nuvectis Pharma Announces Upcoming Poster Presentation for NXP800 at the 2023 AACR Special Conference on Endometrial Cancer
October 24, 2023 08:00 ET
|
Nuvectis Pharma, Inc.
Fort Lee, NJ, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of...
Nuvectis Pharma Announces Updated Date and Time for the 2023 Cantor Global Healthcare Conference Corporate Presentation
September 25, 2023 19:30 ET
|
Nuvectis Pharma, Inc.
Fort Lee, NJ, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of...
Nuvectis Pharma Announces Upcoming Presentations for NXP800 and NXP900
September 21, 2023 08:00 ET
|
Nuvectis Pharma, Inc.
Fort Lee, NJ, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of...
Nuvectis Pharma Announces Initiation of the NXP900 Phase 1a Clinical Trial
September 12, 2023 08:00 ET
|
Nuvectis Pharma, Inc.
Fort Lee, NJ, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of...
Nuvectis Pharma to Host KOL Event to Discuss Its Two Precision Medicine Clinical-Stage Drug Candidates, NXP800 and NXP900
September 06, 2023 08:00 ET
|
Nuvectis Pharma, Inc.
Fort Lee, NJ, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of...